Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Contributed by: Business Wire

Logo

Tags

Biotechnology

Other Health

Health

General Health

Mental Health

Other Science

Veterans

Research

Other Defense

Defense

Science

Compass Pathfinder Limited

More Like This

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET